Fluor Corporation provides engineering, procurement, construction, manufacturing and modularization, operation, maintenance and asset integrity and project management services globally. The company is headquartered in Irving, Texas.
| Revenue (TTM) | $15.54B |
| Gross Profit (TTM) | $-124.00M |
| EBITDA | $-233.00M |
| Operating Margin | 3.26% |
| Return on Equity | -45.20% |
| Return on Assets | -1.93% |
| Revenue/Share (TTM) | $102.54 |
| Book Value | $19.81 |
| Price-to-Book | 2.64 |
| Price-to-Sales (TTM) | 0.43 |
| EV/Revenue | 0.33 |
| EV/EBITDA | 11.10 |
| Quarterly Earnings Growth (YoY) | -94.50% |
| Quarterly Revenue Growth (YoY) | 8.80% |
| Shares Outstanding | $133.74M |
| Float | $131.55M |
| % Insiders | 2.39% |
| % Institutions | 100.35% |
Volatility is currently contracting
The owners and operators of commercial reactors in the U.S. are planning for a larger and longer-lasting fleet. A recent survey of utility companies from the Nuclear Energy Institute (NEI) highlights rising interest in new reactors and expectations for operating lives beyond 80 years.
Here is how Fluor (FLR) and Owens Corning (OC) have performed compared to their sector so far this year.
CALGARY, Alberta — September 10 , 2026 — Leads & Copy — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF), a Canadian company focused on developing pharmaceutical-grade barium and iodine contrast media for medical imaging, has achieved its first milestone under a non-dilutive Collaboration and Funding Agreement with Bayer AG. The company announced that it successfully submitted a complete feasibility work plan and timetable, which has been approved by Bayer. The milestone achievement triggers the first major non-dilutive payment of USD $1,000,000 from Bayer. This payment, combined with the initial USD $350,000 received on March 31, 2026, brings the total funding received by Voyageur from Bayer to USD $1,350,000 of the committed USD $2,350,000.
CALGARY, Alberta – TheNewswire - September 9, 2026 – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) (“ Voyageur ” or the “ Company ”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has achieved the first milestone under its non-dilutive Collaboration and Funding Agreement with Bayer AG (“ Bayer ”) dated February 10, 2026 (the “ Agreement ”) by submitting a complete feasibility work plan and timetable which has been approved by Bayer. (Collaboration funding news https://finance.yahoo.com/news/voyageur-pharmaceuticals-announces-collaboration-bayer-144926270.html )
Investors usually focus on reactor developers and uranium miners when deciding on allocations for investing in the nuclear renaissance. A narrow view on the nuclear sector could result in missed opportunities for investment returns in nuclear-adjacent companies.
Here is how Fluor (FLR) and James Hardie (JHX) have performed compared to their sector so far this year.
Two of the most significant government-led nuclear energy programs are illustrating how quickly the advanced nuclear field is expanding. The Nuclear Energy Launch Pad added 13 reactor and fuel cycle technology projects to its development pipeline.
Fluor Corporation is executing a multi-year turnaround, shifting to reimbursable contracts and leveraging AI to improve project execution and margins. FLR's $27B backlog is nearly 4x its $7.3B market cap, with 85% now reimbursable, reducing legacy fixed-price risk and enhancing earnings visibility. Management's modernization, AI-driven project controls, and focus on high-demand sectors—nuclear, data centers, and defense—increase FLR's strategic positioning.
The U.S. Department of Energy (DOE) has given X-Energy (XE) up to $1 billion in additional public funding support for its high-temperature gas-cooled reactor project in Texas. The funding marks another significant federal commitment to advancing next-generation nuclear power generation to meet growing electricity demands.
Three billionaires, one unglamorous engineering stock, three different answers. In Q2 2026 13F filings disclosing positions as of June 30, 2026 and filed August 14, 2026, Stanley Druckenmiller, George Soros and David Einhorn each moved on Fluor (NYSE:FLR | FLR Price Prediction), and they moved in opposite directions.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FLR and any ticker you trade — then tracks every position and per-strategy win rate.
